Primary Immunodeficiency — T Cell and Combined

• Thymic development and T cell selection defects: The thymus is the primary organ where T cell precursors (derived from bone marrow hematopoietic stem cells) undergo maturation, TCR gene rearrangement, and selection. Disorders affecting thymic epithelial cell development (DiGeorge syndrome/22q11 deletion), T cell receptor recombination (RAG1/RAG2 deficiency), or positive/negative selection processes result in severe depletion or absence of peripheral T cells. In DiGeorge syndrome, underdevelopment of the third and fourth pharyngeal pouches results in thymic hypoplasia or aplasia, directly reducing the number of T cells entering the peripheral circulation. In RAG-deficient SCID, mutations in recombination-activating genes (RAG1 or RAG2)—which encode endonucleases essential for V(D)J recombination—prevent generation of mature T cell and B cell receptors, resulting in profound lymphopenia affecting both T and B cell lineages.

• Signaling cascade defects affecting TCR function and T cell survival: Normal T cell activation requires engagement of the TCR with antigen-MHC complexes and delivery of costimulatory signals through CD28. Downstream signaling involves multiple kinases including Src family kinases (Lck, Fyn), ZAP-70, LAT, and phospholipase C-γ, culminating in calcium mobilization and transcription factor activation (NF-κB, NFAT, AP-1). ZAP-70 deficiency impairs TCR signal transduction, resulting in selective loss of CD8+ T cells (positive selection through TCR signaling is impaired) while CD4+ T cells may be relatively preserved but functionally defective. CD45 deficiency (leukocyte common antigen, PTPRC gene) prevents proper dephosphorylation of TCR-associated proteins, blocking TCR signal initiation. Mutations affecting interleukin-2 receptor (IL-2R) gamma chain (common gamma chain, γc), which is shared among receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, result in impaired growth signaling and survival of T cells, NK cells, and B cells, accounting for X-linked SCID (the most common form of SCID). Similarly, IL-7 receptor (IL-7R) alpha chain deficiency specifically impairs T cell lymphopoiesis, as IL-7 is the critical trophic factor driving T cell development and homeostasis.

• Metabolic defects and nucleotide metabolism: Several SCID forms involve defects in nucleotide metabolism pathways critical for lymphocyte DNA synthesis and survival. Adenosine deaminase (ADA) deficiency results in accumulation of toxic metabolites (deoxyadenosine, deoxyadenosine triphosphate) that are particularly toxic to lymphocytes due to their high rates of cell division and nucleotide turnover; deoxyadenosine triphosphate (dATP) accumulation activates ribonucleotide reductase inhibition and triggers apoptosis through dATP-dependent mechanisms and activation of death pathways. Purine nucleoside phosphorylase (PNP) deficiency leads to accumulation of deoxyinosine and deoxyguanosine, similarly inducing lymphocyte apoptosis; PNP deficiency typically affects T cells more severely than B cells. These metabolic defects produce selective or preferential loss of lymphocytes while relatively sparing other cell types.

• Transcription factor and epigenetic defects: The FOXN1 gene encodes a winged-helix transcription factor essential for thymic epithelial cell development and function; mutations result in severe T cell lymphopenia despite normal hematopoiesis. WHN (Winged helix nude) mutations cause congenital athymia in humans (similar to nude mice lacking functional Foxn1). AIRE (autoimmune regulator) mutations impair negative selection and regulatory T cell (Treg) development, leading to autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), demonstrating how defective central tolerance mechanisms produce T cell dysfunction.

• Combined T and B cell defects with predominant T cell dysfunction: In omenn syndrome (a form of leaky SCID), hypomorphic RAG mutations allow limited V(D)J recombination, resulting in the emergence of autologous T cell clones that attack the body, producing erythroderma, hepatosplenomegaly, lymphadenopathy, and elevation of IgE. In adenosine deaminase-deficient SCID, both T and B cells are affected, but T cell deficiency predominates clinically.

• NK cell and lymphocyte trafficking defects: SCID-X1 (γc deficiency) and other forms impair development of natural killer (NK) cells alongside T cells, removing an important component of innate immunity. DOCK8 deficiency (dedicator of cytokinesis 8) impairs actin polymerization and cellular migration, affecting T cell, B cell, and NK cell trafficking and function, resulting in recurrent sinopulmonary infections and increased susceptibility to viral infections (particularly CMV and EBV).

• Severe Combined Immunodeficiency (SCID) subtypes: SCID represents the most severe form of T cell immunodeficiency, characterized by profound depletion of T lymphocytes with variable B and NK cell involvement. X-linked SCID (SCID-X1) accounts for approximately 45-50% of all SCID cases and results from mutations in the IL2RG gene encoding the common gamma chain (γc); it preferentially affects males and typically presents within the first 3 months of life. Autosomal recessive adenosine deaminase (ADA) deficiency SCID accounts for approximately 10-15% of cases and results from mutations in the ADA gene; presents with T cell lymphopenia, variable B cell numbers, and metabolic manifestations including sensorineural hearing loss and skeletal dysplasia (adenosine accumulates in cartilage). RAG1/RAG2-deficient SCID (autosomal recessive) accounts for approximately 10% of SCID cases and results from mutations preventing V(D)J recombination; produces profound lymphopenia affecting both T and B cells. IL-7 receptor alpha chain deficiency is autosomal recessive, affects T cell development selectively while preserving B and NK cells. JAK3 deficiency (autosomal recessive, accounts for ~5% of SCID) disrupts signaling through γc-containing receptors despite normal γc expression. PRKDC-deficient SCID (DNA-dependent protein kinase catalytic subunit, autosomal recessive) impairs both T cell receptor rearrangement and DNA repair.

• DiGeorge Syndrome (22q11.2 Deletion Syndrome): This is the most common primary immunodeficiency, with an incidence of approximately 1 in 3,000 to 1 in 6,000 live births. The 22q11.2 microdeletion affects multiple genes including TBX1, which is crucial for pharyngeal pouch and thymic development. The severity of T cell deficiency varies widely from partial DiGeorge (mild T cell lymphopenia) to complete DiGeorge (absent thymus); approximately 75% of patients have some degree of T cell deficiency, though most do not have profound immunosuppression. Features result from impaired neural crest cell migration to the 3rd and 4th pharyngeal pouches.

• Combined Immunodeficiency with Predominant T Cell Defects: DOCK8 deficiency (dedicator of cytokinesis 8, autosomal recessive) results in hyper-IgE syndrome-like presentations with recurrent sinopulmonary and cutaneous infections. CD3 delta (CD3D), CD3 epsilon (CD3E), or CD3 zeta (CD3Z) chain deficiency prevents proper TCR assembly and signaling, with autosomal recessive inheritance. LCK deficiency (Src family kinase, autosomal recessive) impairs early TCR signaling steps. ZAP-70 deficiency (autosomal recessive) produces selective CD8+ T cell deficiency with hypomorphic mutations allowing some CD4+ T cell development but with impaired function.

• Thymic Hypoplasia/Aplasia: FOXN1 mutations (autosomal recessive or rarely dominant) cause congenital athymia. TBCE deficiency and other tubulin-folding-cofactor mutations impair thymic epithelial cell structure and function.

• Immunodeficiency with Syndromic Features: SCID-related lymphoid proliferations and Omenn syndrome represent leaky SCID phenotypes with hypomorphic RAG mutations that allow limited but autoreactive T cell development. WHIM syndrome (warts, hypogammaglobulinemia, infections, myelokathexis) results from activating mutations in CXCR4, leading to impaired granulocyte and T cell release from bone marrow.

• Ataxia-Telangiectasia (AT): Autosomal recessive disorder caused by mutations in the ATM gene (ataxia-mutated, serine/threonine kinase involved in DNA damage response); results in progressive T cell lymphopenia, cerebellar ataxia, telangiectasias, and marked predisposition to malignancy. T cell numbers typically decline with age, and thymic involution occurs prematurely.

• Recurrent and opportunistic infections: The hallmark of T cell immunodeficiency is severe, recurrent, or atypical infections beginning early in life. Patients experience bacterial infections (particularly Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus) of the respiratory tract, skin, and bloodstream; viral infections including cytomegalovirus (CMV), herpes simplex virus (HSV), varicella-zoster virus (VZV), respiratory syncytial virus (RSV), parainfluenza, and rhinovirus that are often severe and prolonged; opportunistic infections such as Pneumocystis jirovecii pneumonia (PCP), cryptosporidiosis (particularly common in severe T cell defects), toxoplasmosis, and tuberculosis; and fungal infections including Candida (especially oropharyngeal and esophageal), Aspergillus, and Cryptococcus. The pattern of infections reflects the specific defects (e.g., impaired IL-7 signaling produces T cell deficiency but may relatively spare NK and B cells, whereas γc deficiency affects all three lineages). Severe combined immunodeficiency patients present with failure to thrive, diarrhea, and PCP pneumonia typically within 3-6 months of birth if diagnosis is delayed.

• Failure to thrive and growth retardation: Persistent infections, malabsorption from gastrointestinal infection or infiltration, and metabolic derangements (particularly in ADA deficiency) produce poor weight gain and linear growth. Chronic diarrhea from uncontrolled viral, bacterial, or parasitic infections is a common presenting symptom.

• Lymphadenopathy and hepatosplenomegaly: In Omenn syndrome (leaky SCID), massive lymphadenopathy and hepatosplenomegaly develop due to autoreactive T cell expansion and systemic inflammation. Generalized lymphadenopathy may be present in other T cell defects but is less prominent. In contrast, some forms of SCID (particularly SCID-X1) may present with absent or minimal lymphoid tissue due to profound lymphopenia.

• Skin manifestations: Omenn syndrome characteristically presents with erythroderma (diffuse erythematous rash) often with desquamation, resembling severe seborrheic dermatitis or exfoliative dermatitis; this is driven by aberrant T cell infiltration and activation in skin. Ataxia-telangiectasia features progressive cerebellar ataxia (typically evident by 2-3 years of age, progressing to severe disability by age 10-20 years) and oculocutaneous telangiectasias (dilated capillaries visible in conjunctivae and skin, typically appearing by age 5-7 years). DOCK8 deficiency presents with recurrent cutaneous abscesses and a hyper-IgE-like syndrome.

• Autoimmunity and lymphoproliferation: Paradoxically, T cell immunodeficiencies may present with autoimmune manifestations. APECED (autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy) from AIRE mutations features autoimmune thyroiditis, adrenal insufficiency (Addison disease), type 1 diabetes, hypoparathyroidism, and chronic mucocutaneous candidiasis. IPEX syndrome (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) from FOXP3 mutations presents with severe diarrhea, dermatitis, thyroiditis, and type 1 diabetes due to defective regulatory T cells (Tregs). Omenn syndrome demonstrates both lymphoproliferation and autoimmunity.

• Malignancy: T cell immunodeficiencies confer markedly increased risk of lymphoid malignancies (lymphomas, leukemias) and solid tumors. Ataxia-telangiectasia patients have a 1-4% overall lifetime malignancy risk (100-200 fold increased compared to general population), with leukemias and lymphomas predominating. SCID survivors who receive hematopoietic stem cell transplantation or gene therapy also have long-term malignancy risks.

• Specific syndromic features: DiGeorge syndrome presents with cardiac defects (including conotruncal defects such as truncus arteriosus, tetralogy of Fallot, interrupted aortic arch), cleft palate, hypocalcemia (from parathyroid hypoplasia), renal abnormalities, and learning disabilities—the "CATCH-22" mnemonic (Cardiac, Abnormal facies, Thymic, Cleft palate, Hypocalcemia, 22q11). Ataxia-telangiectasia combines progressive neurologic decline with immunodeficiency. WHIM syndrome features warts (HPV-related), hypogammaglobulinemia, infections, and myelokathexis (abnormal retention of mature neutrophils in bone marrow).

• Delayed presentation and variable penetrance: Some T cell defects present later in childhood or even adulthood. Partial DiGeorge patients may have clinically silent T cell defects throughout life. Ataxia-telangiectasia presents with neurologic symptoms in early childhood, with immune dysfunction becoming apparent only after thymic involution or with immune challenges.

• Physical examination findings: Patients typically have

Initial screening

• **Newborn screening with the TREC assay**: T-cell receptor excision circles are byproducts of V(D)J recombination and serve as a surrogate for thymic output; low or absent TRECs on the dried blood spot flags T-cell lymphopenia before infection develops. SCID is on the HHS/ACHDNC Recommended Uniform Screening Panel and is screened in all US states. A low TREC is a screen, not a diagnosis — it also flags leaky SCID, complete DiGeorge, athymia, and secondary lymphopenia, and it misses defects with normal T-cell numbers but poor function (ZAP-70 deficiency, MHC class II deficiency, late-onset ADA).
• CBC with differential: absolute lymphocyte count is the cheapest clue — persistent lymphopenia in an infant is never normal (infants are normally lymphocyte-predominant).

Confirmatory testing

• Flow cytometry for lymphocyte subsets: the key test. Quantify CD3, CD4, CD8, CD19/20, CD16/56 to assign the T−B−NK−, T−B−NK+, or T−B+NK− pattern that predicts the gene (ADA, RAG, IL2RG/JAK3, IL7Rα). Add naïve CD4+CD45RA+ cells (absent in SCID; maternal or oligoclonal cells are memory-phenotype).
• Lymphocyte proliferation to mitogen (PHA): functional confirmation; markedly reduced in SCID and in functional T-cell defects with normal counts.
• PIDTC criteria are the accepted research/clinical definitions: typical SCID requires profoundly low autologous CD3 T cells (on the order of <300/µL) with severely impaired PHA response or maternal T-cell engraftment; leaky SCID has intermediate T-cell numbers with restricted repertoire, and Omenn syndrome adds erythroderma with eosinophilia and high IgE.
• Genetic confirmation: targeted or panel/exome sequencing establishes the molecular diagnosis and guides transplant conditioning and gene therapy eligibility.

Disease-specific findings

• ADA deficiency: absent erythrocyte ADA activity with elevated dATP; radiographs show costochondral ("cupping/flaring") dysplasia.
• DiGeorge: chromosomal microarray or FISH for 22q11.2 deletion; hypocalcemia with hyperphosphatemia and inappropriately low PTH; absent thymic shadow on chest radiograph.
• Ataxia-telangiectasia: elevated serum alpha-fetoprotein with low IgA, then ATM sequencing.

Immediate stabilization (SCID is a pediatric immunologic emergency)

• Protective isolation and urgent referral to a transplant-capable immunology center; every day of infection before transplant worsens survival.
• Stop all live vaccines — rotavirus, BCG, MMR, varicella, oral polio, LAIV, and live typhoid/yellow fever are contraindicated per ACIP/AAP; also screen and immunize household contacts appropriately.
• Blood products must be irradiated, leukoreduced, and CMV-safe to prevent transfusion-associated graft-versus-host disease and CMV transmission.
• Anti-infective prophylaxis: trimethoprim-sulfamethoxazole for Pneumocystis jirovecii, plus antifungal (e.g., fluconazole) and antiviral (e.g., acyclovir) coverage per IDSA/AAP practice for profoundly T-cell-deficient hosts; treat active infection aggressively before conditioning.
• Immunoglobulin replacement (IVIG or SCIG) to cover the absent or non-functional antibody compartment.
• Hypocalcemia in DiGeorge: calcium plus activated vitamin D (calcitriol); tetany, laryngospasm, or seizure is an emergency.

Definitive therapy

• Allogeneic hematopoietic stem cell transplantation is curative for SCID and is the standard of care endorsed by PIDTC/ASTCT; outcomes are best when performed in the first months of life and before infection occurs, with matched sibling donors giving the highest survival. This is the single argument for newborn screening.
• ADA-deficient SCID: PEG-conjugated bovine ADA enzyme replacement (elapegademase) bridges to definitive therapy; autologous ex vivo gene therapy is an alternative to allogeneic HSCT. Lentiviral gene therapy is also used for X-linked SCID at specialized centers.
• Complete DiGeorge/FOXN1 athymia: cultured allogeneic thymus tissue implantation (FDA-approved as RETHYMIC) restores thymopoiesis — HSCT alone cannot, because the defect is the thymic stroma, not the stem cell.
• Ataxia-telangiectasia: supportive care with IgG replacement and prophylaxis; avoid ionizing radiation and radiomimetic chemotherapy because ATM-deficient cells cannot repair double-strand breaks — use MRI/ultrasound rather than CT.

Infectious complications of the disease

• Pneumocystis jirovecii pneumonia: absent CD4 help permits alveolar proliferation; presents as afebrile tachypnea and hypoxemia with diffuse interstitial infiltrates and a widened A–a gradient. Emergency.
• Disseminated live-vaccine infection: BCG osteomyelitis/disseminated BCG-osis and vaccine-strain rotavirus diarrhea occur because there is no cellular immunity to contain attenuated organisms. Emergency.
• Chronic diarrhea and failure to thrive: cryptosporidial or persistent viral enteritis; cryptosporidiosis may progress to sclerosing cholangitis.
• Overwhelming viral disease (CMV, adenovirus, parainfluenza, RSV): prolonged shedding, pneumonitis, hepatitis; hypoxemic respiratory failure is the terminal event in untreated SCID.
• Bronchiectasis from repeated pneumonias in later-presenting combined immunodeficiency.

Immune dysregulation and neoplasia

• Transfusion-associated GVHD and maternal T-cell engraftment: alloreactive T cells cannot be rejected; look for rash, transaminitis, diarrhea, and cytopenias. Transfusion-associated GVHD is nearly uniformly fatal — an emergency and a preventable error.
• Autoimmune cytopenias, endocrinopathy, and enteropathy: loss of central (AIRE) or peripheral (FOXP3) tolerance.
• EBV-driven lymphoproliferation and lymphoma: absent cytotoxic T-cell surveillance; DOCK8 deficiency adds HPV-driven squamous carcinoma. Ataxia-telangiectasia carries a markedly elevated risk of leukemia and lymphoma.

Complications of treatment

• Acute and chronic GVHD after allogeneic HSCT; skin, gut, and liver involvement.
• Conditioning toxicity: mucositis, veno-occlusive disease, infertility, and secondary malignancy from alkylators.
• Incomplete B-cell reconstitution after unconditioned transplant — persistent hypogammaglobulinemia requiring lifelong IgG replacement despite T-cell recovery.
• Insertional oncogenesis: early gamma-retroviral gene therapy for X-linked SCID caused T-lymphoblastic leukemia via activation of a proto-oncogene near the integration site; self-inactivating lentiviral vectors were developed in response.
• Radiation-induced malignancy and severe chemotherapy toxicity in ataxia-telangiectasia.
• Hypocalcemic seizure or laryngospasm in DiGeorge, and progressive cerebellar and bulbar decline with aspiration in ataxia-telangiectasia.

• Absent thymic shadow + lymphopenia + PCP in a 4-month-old = SCID. The single best next step is flow cytometry for lymphocyte subsets, not immunoglobulin levels — infant IgG is confounded by maternal antibody.
• **Newborn screening detects SCID by low/absent *TREC*s.** Remember what TREC measures: thymic output. A normal TREC does not exclude functional defects such as ZAP-70 or MHC class II deficiency.
• Match the flow pattern to the gene: T−B+NK− = IL2RG (X-linked, most common) or JAK3; T−B+NK+ = IL7Rα; T−B−NK+ = RAG1/2; T−B−NK− = ADA deficiency (add costochondral cupping, sensorineural hearing loss).
• Erythroderma + lymphadenopathy + hepatosplenomegaly + eosinophilia + high IgE in an infant = Omenn syndrome from hypomorphic RAG mutations — a leaky SCID, not atopic dermatitis.
• Neonatal seizure + conotruncal cardiac defect + low PTH = 22q11.2 deletion; order chromosomal microarray/FISH. Give calcium plus calcitriol, and remember most 22q11 patients have only partial T-cell deficiency.
• The association examiners love: irradiated, leukoreduced, CMV-negative blood products and no live vaccines in any suspected T-cell defect. Giving rotavirus vaccine or unirradiated packed cells is the trap answer.
• Ataxia + telangiectasia + elevated AFP + low IgA = ataxia-telangiectasia; the tested management point is avoid ionizing radiation (no CT, no radiomimetic chemotherapy) because ATM cannot repair double-strand breaks.
• Definitive therapy is HSCT, and earlier is better — before infection and in the first months of life. Distractor to avoid: HSCT alone does not correct complete DiGeorge or FOXN1 athymia, where the defect is thymic stroma and thymus tissue implantation is required; ADA deficiency uniquely also has enzyme replacement and gene therapy options.